LBT Innovations Limited (AU:LBT) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Australian medical technology firm LBT Innovations has secured a lucrative deal with AstraZeneca, involving the sale of five APAS® Independence instruments and a seven-year maintenance contract, potentially reaching AU$4.1 million. This agreement, following positive validation studies, highlights the growing commercial interest from large pharmaceutical companies in LBT’s AI-driven microbiology automation technology. The initial installations are slated for the upcoming six months, with expectations of further orders.
For further insights into AU:LBT stock, check out TipRanks’ Stock Analysis page.